RX-3117 manufacturers
- RX-3117
-
- $159.00
-
2026-04-21
- CAS:865838-26-2
- Purity: 97.46%
- Supply Ability: 10g
|
| | RX-3117 Basic information |
| Product Name: | RX-3117 | | Synonyms: | RX-3117;4-Amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl]-2(1H)-pyrimidinone;RX-3117; RX3117; RX 3117; TV-1360; TV1360; TV 1360; FLUOROCYCLOPENTENYLCYTOSINE;TV 1360;TV1360;TV-1360;CS-1677;2(1H)-Pyrimidinone, 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl]- | | CAS: | 865838-26-2 | | MF: | C10H12FN3O4 | | MW: | 257.22 | | EINECS: | | | Product Categories: | | | Mol File: | 865838-26-2.mol |  |
| | RX-3117 Chemical Properties |
| Boiling point | 516.3±60.0 °C(Predicted) | | density | 1.82±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:50.0(Max Conc. mg/mL);194.39(Max Conc. mM) | | pka | 12.88±0.70(Predicted) | | form | Powder | | color | White to off-white | | InChI | InChI=1S/C10H12FN3O4/c11-6-4(3-15)8(16)9(17)7(6)14-2-1-5(12)13-10(14)18/h1-2,7-9,15-17H,3H2,(H2,12,13,18)/t7-,8-,9+/m1/s1 | | InChIKey | QLLGKCJUPWYJON-HLTSFMKQSA-N | | SMILES | C1(=O)N([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)C=CC(N)=N1 |
| | RX-3117 Usage And Synthesis |
| Uses | RX-3117 (TV-1360) is a potent and orally active anticancer and antimetaboliteagent. RX-3117 inhibits DNA methyltransferase 1 (DNMT1). RX-3117 shows antiproliferative and anti-tumour activity. RX-3117 induces cell cycle arrest at S phase and apoptosis[1][2][3]. | | Definition | ChEBI: Roducitabine is a triol that is (1S,2R)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol which is substituted by a 4-amino-2-oxopyrimidin-1(2H)-yl group at position 5. It is a cytidine analog which exhibits anticancer activity in several cancers, including gemcitabine-resistant tumours. It has a role as an antimetabolite, an antineoplastic agent, a prodrug, a DNA synthesis inhibitor and an apoptosis inducer. It is an organofluorine compound, a primary allylic alcohol and a triol. | | in vivo | RX-3117 (2, 10 mg/kg; i.p.; three times per week for five weeks) shows anti-tumour activity in nude mice[3]. | Animal Model: | Nude mice (human colon carcinoma HCT116 xenograft model)[3] | | Dosage: | 2, 10 mg/kg | | Administration: | I.p.; three times per week for five weeks | | Result: | Caused significant inhibition of tumor growth at the doses of 2 and 10 mg/kg. |
| | References | [1] Sarkisjan D, et al. The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2. PLoS One. 2016 Sep 9;11(9):e0162901. DOI:10.1371/journal.pone.0162901
[2] Balboni B, et al. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. DOI:10.1080/13543784.2019.1583742
[3] Fahy J, et al. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012 Dec;22(12):1427-42. DOI:10.1517/13543776.2012.729579 |
| | RX-3117 Preparation Products And Raw materials |
|